MVM LEADS $33m SERIES C IN VITAL CONNECT, INC
Vital Connect, Inc. is a leader in medical-grade wearable biosensor systems
Read moreMVM CLOSES MVM IV
MVM Life Science Partners LLP has announced the closing of a $233 million healthcare fund, MVM IV. The fund is MVM’s fourth and largest raised to date
Read moreMVM INVESTS €15.2 MILLION IN VALNEVA SE
Valneva is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera
Read moreMVM LEADS $10.5M FINANCING IN PROVIDENCE MEDICAL
Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing
Read moreWILSON THERAPEUTICS' WTX101 MEETS PRIMARY ENDPOINT
Wilson Therapeutics AB has announced that the Phase II study of WTX101, an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint
Read more
MVM Overview
- • Venture capital and growth equity investor in healthcare companies since 1997
- • More than $700 million under management across several funds
- • Investment teams in Boston and London provide global perspective and coverage
- • Partners of MVM have more than 80 years of healthcare investment experience
Recent News
VitalConnect Announces Closure of $33m Series C Financing
VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter Ventures.
Providence Medical Technology announces new equity financing of $10.5 million
Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.